Eric Schmidt's most recent trade in Revolution Medicines Inc was a trade of 18,400 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 8, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 5,200 | 21,251 (0%) | 0% | 0 | Common Stock | |
| Relmada Therapeutics Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 92,958 | 150,000 | - | - | Stock Option (right to buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 558,094 | 862,439 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 432,738 | 432,738 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 14 Mar 2023 | 35,879 | 304,345 (0%) | 0% | 5.5 | 196,258 | Common Stock |
| Relmada Therapeutics Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 57,042 | 57,042 | - | - | Stock Option (right to buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 5,200 | 16,051 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 368,589 | 368,589 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 237,358 | 337,904 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Eric Schmidt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 15 Mar 2022 | 11,469 | 100,546 (0%) | 0% | 7.6 | 87,551 | Common Stock |
| Relmada Therapeutics Inc | Eric Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 58,765 | 58,765 | - | - | Stock Option (right to buy) |